S&P 500 7,722.60 ▲ 45.83 (+0.60%) DOW 52,377.57 ▲ 15.97 (+0.03%) NASDAQ 26,477.81 ▲ 308.43 (+1.18%) US Markets Closed â€ĸ 05:33 AM ET

PHVS

Pharvaris N.V.

Price Chart
Latest Quote

$31.95

+0.41 (+1.30%)
Current Price
Previous Close $31.54
Open $31.62
Day High $32.33
Day Low $31.59
Volume 230,110
Fetched: 2026-10-28T09:33:23
Stock Information
Note: Financial values converted from EUR to USD
Shares Outstanding 70.20M
Total Debt $750K
Cash Equivalents $354.12M
Net Income $-190.17M
Sector Healthcare
Industry Biotechnology
Market Cap $2.24B
EPS (TTM) $-3.06
Exchange NMS
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$1.93B
Income$-190.17M
Book/sh$4.81
Cash/sh$4.53
Employees148
Financial Ratios
Quick Ratio11.82
Current Ratio11.94
Debt/Eq0.22
Returns & Margins
ROA-42.32%
ROE-70.46%
Ownership
Insider Ownership6.31%
Institutional Ownership93.40%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-10.45
P/B6.64
Analyst Data
Recommendationstrong_buy
Target Price$57.28
Technical Indicators
SMA20$30.73
SMA50$33.84
SMA200$30.88
RSI51.56
ATR1.3339
Shares Float44.13M
Short Float4.26%
Short Ratio3.40
Volatility-2.46
Rel Volume0.36
Performance History
Week+3.40%
Month+0.13%
Quarter-2.05%
6 Months+13.22%
YTD+20.66%
Year+38.97%
3 Years+84.79%
5 Years+109.92%
10 Years+10.17%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-10-27 $31.95 230,100
2026-10-26 $31.54 347,300
2026-10-23 $31.41 621,700
2026-10-22 $30.68 347,200
2026-10-21 $30.66 393,500
2026-10-20 $30.90 1,029,000
2026-10-19 $29.77 917,100
2026-10-16 $27.74 1,307,600
2026-10-15 $29.64 820,400
2026-10-14 $30.02 400,400
2026-10-13 $30.02 443,900
2026-10-12 $30.89 646,000
2026-10-09 $31.10 755,000
2026-10-08 $31.12 628,200
2026-10-07 $31.68 341,800
2026-10-06 $31.12 778,400
2026-10-05 $30.49 816,200
2026-10-02 $31.19 591,400
2026-10-01 $31.01 654,300
2026-09-30 $31.72 839,800
2026-09-29 $31.73 459,200
2026-09-28 $31.91 753,300
About Pharvaris N.V.

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

📰 Latest News
No news articles available at the moment. Check back later for updates on PHVS.
Period:
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Total Expenses $189,049,248 $162,182,093 $107,885,589 $96,531,907
Other Income Expense $-11,411,276 $8,760,007 $-3,469,511 $12,357,111
Net Non Operating Interest Income Expense $7,082,473 $6,036,458 $227,117 $-43,698
Total Other Finance Cost $-7,082,473 $-6,036,458 $-227,117 $43,698
Operating Expense $189,049,248 $162,182,093 $107,885,589 $96,531,907
General And Administrative Expense $50,478,237 $52,459,802 $34,886,554 $32,660,620
Interest Expense - - - $17,928
Interest Expense Non Operating - - - $17,928
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-195,591,011 $-149,417,270 $-112,295,528 $-84,974,463
Net Interest Income $7,082,473 $6,036,458 $227,117 $-43,698
Normalized Income $-187,123,844 $-155,917,195 $-109,721,150 $-94,143,440
Net Income From Continuing And Discontinued Operation $-195,591,011 $-149,417,270 $-112,295,528 $-84,974,463
Net Income Common Stockholders $-195,591,011 $-149,417,270 $-112,295,528 $-84,974,463
Net Income $-195,591,011 $-149,417,270 $-112,295,528 $-84,974,463
Net Income Including Noncontrolling Interests $-195,591,011 $-149,417,270 $-112,295,528 $-84,974,463
Net Income Continuous Operations $-195,591,011 $-149,417,270 $-112,295,528 $-84,974,463
Pretax Income $-193,378,052 $-147,385,627 $-111,127,984 $-84,218,494
Operating Income $-189,049,248 $-162,182,093 $-107,885,589 $-96,531,907
Per Share
Diluted EPS $-3.31 $-2.76 $-2.93 $-2.53
Basic EPS $-3.31 $-2.76 $-2.93 $-2.53
Other
Tax Effect Of Unusual Items $-2,944,109 $2,260,082 $-895,134 $3,188,135
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-177,172,256 $-170,642,019 $-104,129,368 $-108,718,762
Total Unusual Items $-11,411,276 $8,760,007 $-3,469,511 $12,357,111
Total Unusual Items Excluding Goodwill $-11,411,276 $8,760,007 $-3,469,511 $12,357,111
Reconciled Depreciation $465,716 $300,080 $286,709 $170,256
EBITDA (Bullshit earnings) $-188,583,532 $-161,882,012 $-107,598,880 $-96,361,651
EBIT $-189,049,248 $-162,182,093 $-107,885,589 $-96,531,907
Diluted Average Shares $65,856,896 $60,136,426 $42,738,123 $37,388,375
Basic Average Shares $65,856,896 $60,136,426 $42,738,123 $37,388,375
Diluted NI Availto Com Stockholders $-195,591,011 $-149,417,270 $-112,295,528 $-84,974,463
Tax Provision $2,212,959 $2,031,642 $1,167,544 $755,969
Gain On Sale Of Security $-11,411,276 $8,760,007 $-3,469,511 $12,357,111
Research And Development $138,571,012 $109,722,291 $72,999,035 $63,871,286
Selling General And Administration $50,478,237 $52,459,802 $34,886,554 $32,660,620
Other Gand A $24,718,665 $31,438,196 $20,064,824 $17,648,935
Salaries And Wages $25,759,571 $21,021,606 $14,821,730 $15,011,685
Insurance And Claims - - $6,714,364 $7,173,226
Fetched: 2026-10-28
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $301,986,359 $298,074,979 $427,528,020 $166,157,227
Total Assets $335,583,895 $324,362,439 $443,832,220 $186,722,688
Total Non Current Assets $2,545,667 $2,176,544 $938,551 $986,577
Non Current Deferred Assets $987,813 $528,050 $431,403 $289,216
Non Current Deferred Taxes Assets $987,813 $528,050 $431,403 $289,216
Current Assets $333,038,228 $322,185,895 $442,893,670 $185,736,111
Prepaid Assets $3,270,862 $6,397,668 $5,521,417 $4,502,121
Receivables $5,066,373 $3,277,874 $1,156,656 $425,769
Taxes Receivable $5,066,373 $3,277,874 $1,156,656 $425,769
Cash Cash Equivalents And Short Term Investments $324,700,992 $312,510,353 $435,524,496 $180,159,676
Cash And Cash Equivalents $324,700,992 $312,510,353 $435,524,496 $180,159,676
Other Current Assets - - $691,100 $648,546
Accounts Receivable - - - $0
Debt
Total Debt $864,742 $959,000 $265,952 $486,276
Long Term Debt And Capital Lease Obligation $641,862 $711,392 $48,496 $277,656
Current Debt And Capital Lease Obligation $222,880 $247,609 $217,456 $208,621
Liabilities
Total Liabilities Net Minority Interest $33,597,536 $26,287,460 $16,304,200 $20,565,461
Total Non Current Liabilities Net Minority Interest $641,862 $711,392 $48,496 $277,656
Current Liabilities $32,955,673 $25,576,068 $16,255,704 $20,287,806
Payables And Accrued Expenses $20,006,037 $16,614,898 $9,479,094 $16,771,751
Payables $6,740,950 $5,748,800 $3,717,741 $7,955,452
Total Tax Payable $1,047,767 $669,317 $478,595 $1,299,359
Accounts Payable $5,693,183 $5,079,484 $3,239,146 $6,656,093
Other Non Current Liabilities - - - -
Equity
Common Stock Equity $301,986,359 $298,074,979 $427,528,020 $166,157,227
Total Equity Gross Minority Interest $301,986,359 $298,074,979 $427,528,020 $166,157,227
Stockholders Equity $301,986,359 $298,074,979 $427,528,020 $166,157,227
Gains Losses Not Affecting Retained Earnings $56,212,815 $44,360,270 $31,036,640 $22,501,113
Other Equity Adjustments $56,513,570 $44,206,952 $31,052,875 $22,452,922
Retained Earnings $-645,214,665 $-447,795,865 $-296,024,313 $-182,777,357
Other
Ordinary Shares Number $72,593,335 $60,536,005 $58,210,191 $37,644,952
Share Issued $72,593,335 $60,536,005 $58,210,191 $37,644,952
Tangible Book Value $301,986,359 $298,074,979 $427,528,020 $166,157,227
Invested Capital $301,986,359 $298,074,979 $427,528,020 $166,157,227
Working Capital $300,082,554 $296,609,827 $426,637,966 $165,448,306
Capital Lease Obligations $864,742 $959,000 $265,952 $486,276
Total Capitalization $301,986,359 $298,074,979 $427,528,020 $166,157,227
Foreign Currency Translation Adjustments $-300,756 $153,318 $-16,235 $48,191
Additional Paid In Capital $882,277,010 $694,246,253 $685,530,463 $321,916,075
Capital Stock $8,711,200 $7,264,321 $6,985,231 $4,517,395
Common Stock $8,711,200 $7,264,321 $6,985,231 $4,517,395
Long Term Capital Lease Obligation $641,862 $711,392 $48,496 $277,656
Current Capital Lease Obligation $222,880 $247,609 $217,456 $208,621
Pensionand Other Post Retirement Benefit Plans Current $12,726,757 $8,713,562 $6,559,153 $3,307,434
Current Accrued Expenses $13,265,087 $10,866,098 $5,761,353 $8,816,299
Net PPE $1,557,855 $1,648,494 $507,148 $697,361
Accumulated Depreciation $-455,623 $-245,058 $-139,567 $-72,944
Gross PPE $2,013,478 $1,893,552 $646,715 $770,305
Other Properties $2,013,478 $1,893,552 $646,715 $770,305
Fetched: 2026-10-28
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-152,775,531 $-134,329,603 $-103,683,715 $-74,904,746
Operating Activities
Operating Cash Flow $-152,592,275 $-133,730,598 $-103,583,544 $-74,766,378
Cash Flow From Continuing Operating Activities $-152,592,275 $-133,730,598 $-103,583,544 $-74,766,378
Operating Gains Losses $13,071,811 $-8,158,787 $3,110,804 $-12,357,111
Investing Activities
Capital Expenditure $-183,256 $-599,005 $-100,171 $-138,368
Investing Cash Flow $-183,256 $-599,005 $-100,171 $-138,368
Cash Flow From Continuing Investing Activities $-183,256 $-599,005 $-100,171 $-138,368
Financing Activities
Issuance Of Capital Stock $191,180,736 $2,498,288 $381,733,645 $10,697,835
Financing Cash Flow $178,790,189 $2,979,578 $362,232,011 $9,629,710
Cash Flow From Continuing Financing Activities $178,790,189 $2,979,578 $362,232,011 $9,629,710
Net Other Financing Charges $-12,146,739 $659,023 $-19,256,163 $-935,066
Net Common Stock Issuance $191,180,736 $2,498,288 $381,733,645 $10,697,835
Common Stock Issuance $191,180,736 $2,498,288 $381,733,645 $10,697,835
Other
Repayment Of Debt $-243,808 $-177,732 $-245,471 $-133,059
End Cash Position $324,700,992 $312,510,353 $435,524,496 $180,159,676
Beginning Cash Position $312,510,353 $435,524,496 $180,159,676 $233,054,817
Effect Of Exchange Rate Changes $-13,824,018 $8,335,881 $-3,183,474 $12,379,895
Changes In Cash $26,014,658 $-131,350,025 $258,548,295 $-65,275,036
Net Issuance Payments Of Debt $-243,808 $-177,732 $-245,471 $-133,059
Net Long Term Debt Issuance $-243,808 $-177,732 $-245,471 $-133,059
Long Term Debt Payments $-243,808 $-177,732 $-245,471 $-133,059
Net PPE Purchase And Sale $-183,256 $-599,005 $-100,171 $-138,368
Purchase Of PPE $-183,256 $-599,005 $-100,171 $-138,368
Taxes Refund Paid $-2,414,266 $-3,080,538 $-1,233,897 $-203,522
Interest Received Cfo $457,258 $6,030,384 $263,878 -
Change In Working Capital $8,487,453 $6,556,783 $-6,526,389 $9,325,282
Change In Other Current Assets $1,943,059 $-151,791 $-1,061,851 $-2,795,365
Change In Payables And Accrued Expense $6,913,245 $6,746,775 $-5,418,839 $11,767,076
Change In Accrued Expense $6,942,088 $4,906,438 $-774,522 $7,419,435
Change In Payable $-28,842 $1,840,337 $-4,644,317 $4,347,641
Change In Receivables $-368,851 $-38,201 $-45,699 $353,570
Other Non Cash Items $-489,359 $-6,036,458 $-227,117 $43,698
Stock Based Compensation $21,207,163 $18,043,564 $11,870,451 $12,634,087
Depreciation Amortization Depletion $465,716 $300,080 $286,709 $170,256
Depreciation And Amortization $465,716 $300,080 $286,709 $170,256
Depreciation $465,716 $300,080 $286,709 $170,256
Net Foreign Currency Exchange Gain Loss $13,071,811 $-8,158,787 $3,110,804 $-12,357,111
Net Income From Continuing Operations $-193,378,052 $-147,385,627 $-111,127,984 $-84,218,494
Interest Paid Cfo - - - $-160,573
Fetched: 2026-10-28